Biomarkers and HIV-associated cardiovascular disease

Current Opinion in HIV and AIDS

Volumn 5, Issue 6, 2010, Pages 511-516

  Baker, Jason V ^a,b   Duprez, Daniel ^c  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b HENNEPIN COUNTY MEDICAL CENTER   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Biomarkers; cardiovascular disease; coagulation; endothelial dysfunction; HIV infection; inflammation; lipoproteins; thrombosis

Indexed keywords

ANTIRETROVIRUS AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; D DIMER; HIGH DENSITY LIPOPROTEIN; INTERLEUKIN 6; LIPID; LIPOPROTEIN;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DISEASE ASSOCIATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLAMMATION; MORTALITY; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; THROMBOSIS; VIRUS REPLICATION;

BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; HIV INFECTIONS; HUMANS;

EID: 78049246978     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e32833ed7ec     Document Type: Review

References (85)

1. Grinspoon SK, Grunfeld C, Kotler DP, et al. State of the science conference: initiative to decrease cardiovascular risk and increase quality of care for patients living with HIV/AIDS - executive summary. Circulation 2008; 118:198-210.
2. Crum NF, Riffenburgh RH, Wegner S, et al. Comparisons of causes of death and mortality rates among HIV-infected persons: analysis of the pre-, early, and late HAART (highly active antiretroviral therapy) eras. J Acquir Immune Defic Syndr 2006; 41:194-200.
3. Mocroft A, Reiss P, Gasiorowski J, et al. Serious fatal and nonfatal non-AIDS-defining illnesses in Europe [abstract #707]. In: Program and Abstracts of the 16th Conference on Retroviruses and Opportunistic Infections; 8-11 February 2009; Montreal, California, USA.
4. El-Sadr WM, Lundgren JD, Neaton JD, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355:2283-2296.
5. Friis-Moller N, Reiss P, Sabin CA, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007; 356:1723-1735.
6. Baker JV, Henry WK, Neaton JD. The consequences of HIV infection and antiretroviral therapy use for cardiovascular disease risk: shifting paradigms. Curr Opin HIV AIDS 2009; 4:176-182.
7. Saves M, Chene G, Ducimetiere P, et al. Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general population. Clin Infect Dis 2003; 37:292-298.
8. Neuhaus J, Jacobs DR, Baker JV, et al. Markers of inflammation, coagulation, and renal function in HIV-infected adults in SMART and in two large popula tion-based cohorts. J Infect Dis (in press).
9. Hsue PY, Hunt PW, Schnell A, et al. Role of viral replication, antiretroviral therapy, and immunodeficiency in HIV-associated atherosclerosis. AIDS 2009; 23:1059-1067.
10. Baker JV, INSIGHT SMART Study Group. Levels of inflammatory and coagulation markers after starting antiretroviral therapy [abstract #280]. Program and Abstracts of the 47th Annual Meeting of the Infectious Diseases Society of America; 29 October-1 November 2009; Philadelphia, USA.
11. Boger MS, Shintani A, Redhage LA, et al. Highly sensitive C-reactive protein, body mass index, and serum lipids in HIV-infected persons receiving antiretroviral therapy: a longitudinal study. J Acquir Immune Defic Syndr 2009; 52:480-487.
12. Kristoffersen US, Kofoed K, Kronborg G, et al. Reduction in circulating markers of endothelial dysfunction in HIV-infected patients during antiretroviral therapy. HIV Med 2009; 10:79-87.
13. van Vonderen MG, Smulders YM,Stehouwer CD, et al. Carotid intima-media thickness and arterial stiffness in HIV-infected patients: the role of HIV, antiretroviral therapy, and lipodystrophy. J Acquir Immune Defic Syndr 2009; 50:153-161.
14. Kuller LH, Tracy R, Belloso W, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 2008; 5:e203.
15. Triant VA, Meigs JB, Grinspoon SK. Association of C-reactive protein and HIV infection with acute myocardial infarction. J Acquir Immune Defic Syndr 2009; 51:268-273.
16. Baker J, Ayenew W, Quick H, et al. High-density lipoprotein particles and markers of inflammation and thrombotic activity in patients with untreated HIV infection. J Infect Dis 2010; 201:285-292.
17. Smith KY, Fine DM, Patel P, et al. Similarity in efficacy and safety of abacavir/lamivudine (ABC/3TC) compared to tenofovir/emtricitabine (TDF/FTC) in combination with QD lopinavir/ritonavir (LPV/r) over 96 weeks in the HEAD Study [abstract #LBPE 1138]. In: Program and Abstracts of the 17th International AIDS Conference; 3-8 August 2008; Mexico City, Mexico.
18. Madden E, Lee G, Kotler DP, et al. Association of antiretroviral therapy with fibrinogen levels in HIV-infection. AIDS 2008; 22:707-715.
19. Tien PC, Choi AI, Zolopa AR, et al. Inflammation and mortality in HIV-infected adults: analysis of the FRAM Study cohort [abstract #725]. In: Program and Abstracts of the 17th Conference on Retroviruses and Opportunistic Infections (CROI); 16-19 February 2010; San Francisco, California, USA.
20. Calmy A, Gayet-Ageron A, Montecucco F, et al. HIV increases markers of cardiovascular risk: results from a randomized, treatment interruption trial. AIDS 2009; 23:929-939.
21. Wolf K, Tsakiris DA, Weber R, et al. Antiretroviral therapy reduces markers of endothelial and coagulation activation in patients infected with human im munodeficiency virus type 1. J Infect Dis 2002; 185:456-462.
22. Ford ES, Greenwald JH, Richterman AG, et al. Traditional risk factors and D- dimer predict incident cardiovascular disease events in chronic HIV infection. AIDS 2010; 24:1509-1517.
23. Melendez MM, McNurlan MA, Mynarcik DC, et al. Endothelial adhesion molecules are associated with inflammation in subjects with HIV disease. Clin Infect Dis 2008; 46:775-780.
24. Ross AC, Armentrout R, O'Riordan MA, et al. Endothelial activation markers are linked to HIV status and are independent of antiretroviral therapy and lipoatrophy. J Acquir Immune Defic Syndr 2008; 49:499-506.
25. Papasavvas E, Azzoni L, Pistilli M, et al. Increased soluble vascular cell adhesion molecule-1 plasma levels and soluble intercellular adhesion mole-cule-1 during antiretroviral therapy interruption and retention of elevated soluble vascular cellular adhesion molecule-1 levels following resumption of antiretroviral therapy. AIDS 2008; 22:1153-1161.
26. van Vonderen MG, Hassink EA, van Agtmael MA, et al. Increase in carotid artery intima-media thickness and arterial stiffness but improvement in several markers of endothelial function after initiation of antiretroviral therapy. J Infect Dis 2009; 199:1186-1194.
27. Duprez D, INSIGHT SMART Study Group. N-terminal-proB-type natriuretic peptide (NT-proBNP) predicts cardiovascular disease events in HIV-infected patients: results of the SMART study [abstract #712]. In: Program and Abstracts of the 17th Conference on Retroviruses and Opportunistic Infec tions (CROI); 16-19 February 2010; San Francisco, California, USA.
28. Riddler SA, Li X, Otvos J, et al. Antiretroviral therapy is associated with an atherogenic lipoprotein phenotype among HIV-1-infected men in the Multi-center AIDS Cohort Study. J Acquir Immune Defic Syndr 2008; 48:281-288.
29. Duprez DA, Kuller LH, Tracy R, et al. Lipoprotein particle subclasses, cardiovascular disease and HIV infection. Atherosclerosis 2009; 207:524-529.
30. Sodora DL, Silvestri G. Immune activation and AIDS pathogenesis. AIDS 2008; 22:439-446.
31. Tracy RP. Epidemiological evidence for inflammation in cardiovascular disease. Thromb Haemost 1999; 82:826-831.
32. Taubes G. Cardiovascular disease. Does inflammation cut to the heart of the matter? Science 2002; 296:242-245.
33. Kuller LH, Tracy RP, Shaten J, Meilahn EN. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Multiple Risk Factor Intervention Trial. Am J Epidemiol 1996; 144:537-547.
34. Harris TB, Ferrucci L, Tracy RP, et al. Associations of elevated interleukin-6, C-reactive protein levels with mortality in the elderly. Am J Med 1999; 106:506-512.
35. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentrations of interleukin-6 and the risk for future myocardial infarction among apparently healthy men. Circulation 2000; 101:1767-1772.
36. Danesh J, Kaptoge S, Mann AG, et al. Long-term interleukin-6 levels and subsequent risk of coronary heart disease: two new prospective studies and a systematic review. PLoS Med 2008; 5:e78.
37. Buckley DI, Fu R, Freeman M, et al. C-reactive protein as a risk factor for coronary heart disease: a systematic review and meta-analyses for the U.S. Preventive Services Task Force. Ann Intern Med 2009; 151:483-495.
38. Heinrich PC, Castell JV, Andus T. Interleukin-6 and the acute phase response. Biochem J 1990; 265:621-636.
39. Kerr R, Stirling D, Ludlam CA. Interleukin 6 and haemostasis. Br J Haematol 2001; 115:3-12.
40. Brenchley JM, Price DA, Schacker TW, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006; 12:1365-1371.
41. Appay V, Sauce D. Immune activation and inflammation in HIV-1 infection: causes and consequences. J Pathol 2008; 214:231-241.
42. Bussolino F, Mitola S, Serini G, et al. Interactions between endothelial cells and HIV-1. Int J Biochem Cell Biol 2001; 33:371-390.
43. Decrion AZ, Dichamp I, Varin A, Herbein G. HIV and inflammation. Curr HIV Res 2005; 3:243-259.
44. Lehmann C, Harper JM,Taubert D, et al. Increased interferon alpha expression in circulating plasmacytoid dendritic cells of HIV-1-infected patients. J Acquir Immune Defic Syndr 2008; 48:522-530.
45. Reingold J, Wanke C, Kotler D, et al. Association of HIV infection and HIV/HCV coinfection with C-reactive protein levels: the fat redistribution and metabolic change in HIV infection (FRAM) study. J Acquir Immune DeficSyndr 2008; 48:142-148.
46. Paton NI, Group TISS. Association between activation inflammatory and coagulation pathways and mortality during long-term follow up in SMART. In: Program and Abstracts of the 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention; 19-22 July 2009; Cape Town, South Africa.
47. Young EM, Considine RV, Sattler FR, et al. Changes in thrombolytic and inflammatory markers after initiation of indinavir- or amprenavir-based antiretroviral therapy. Cardiovasc Toxicol 2004; 4:179-186.
48. SMART/INSIGHT, DAD Study Groups. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the SMART study. AIDS 2008; 22:F17-F24.
49. Kristoffersen US, Kofoed K, Kronborg G, et al. Changes in biomarkers of cardiovascular risk after a switch to abacavir in HIV-1-infected individuals receiving combination antiretroviral therapy. HIV Med 2009; 10:627-633.
50. Martinez E, Larrousse M, Podzamczer D, et al. Abacavir-based therapy does not affect biological mechanisms associated with cardiovascular dysfunction. AIDS 2010; 24:F1-F9.
51. Martin A, Amin J, Cooper D, et al. Changes in cardiovascular biomarkers with abacavir: a randomized, 96-week trial [abstract #718]. In: Program and Abstracts of the 17th Conference on Retroviruses and Opportunistic Infections (CROI); 16-19 February 2010; San Francisco, California, USA.
52. Wang TJ, Gona P, Larson MG, et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. New Engl J Med 2006; 355:2631-2639.
53. Woodward M, Lowe GDO, Rumley A, Tunstall-Pedoe H. Fibrinogen as a risk factor for coronary heart disease and mortality in middle-aged men and women. The Scottish Heart Health Study. Eur Heart J 1998; 19:55-62.
54. Shen YM, Frenkel EP. Thrombosis and a hypercoagulable state in HIV-infected patients. Clin Appl Thromb Hemost 2004; 10:277-280.
55. Bissuel F, Berruyer M, Causse X, et al. Acquired protein S deficiency: correlation with advanced disease in HIV-1-infected patients. J Acquir Immune Defic Syndr 1992; 5:484-489.
56. Stahl CP, Wideman CS, SpiraTJ, et al. Protein S deficiency in men with long-term human immunodeficiency virus infection. Blood 1993; 81:1801-1807.
57. Abuaf N, LapercheS, Rajoely B, et al. Autoantibodies to phospholipids and to the coagulation proteins in AIDS. Thromb Haemost 1997; 77:856-861.
58. Blann AD, Seigneur M, Constans J, et al. Soluble P-selectin, thrombocytopenia and von Willebrand factor in HIV infected patients. Thromb Haemost 1997; 77:1221-1222.
59. Blann A, Constans J, Dignat-George F, Seigneur M. The platelet and endothelium in HIV infection. Br J Haematol 1998; 100:613-614.
60. Erbe M, Rickerts V, Bauersachs RM, Lindhoff-Last E. Acquired protein C and protein S deficiency in HIV-infected patients. Clin Appl Thromb Hemost 2003; 9:325-331.
61. Schecter AD, Berman AB, Yi L, et al. HIV envelope gp120 activates human arterial smooth muscle cells. Proc Natl Acad Sci USA 2001; 98:10142-10147.
62. Funderburg NT, Mayne E, Sieg SF, et al. Increased tissue factor expression on circulating monocytes in chronic HIV infection: relationship to in vivo coagula tion and immune activation. Blood 2010; 115:161-167.
63. Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice - a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003; 107:499-511.
64. Blake GJ, Ridker PM. Novel clinical markers of vascular wall inflammation. Circ Res 2001; 89:763-771.
65. Blann AD. Endothelial cell activation, injury, damage and dysfunction: separate entities or mutual terms? Blood Coagul Fibrinolysis 2000; 11:623-630.
66. Kohler HP, Grant PJ. Plasminogen-activator inhibitor type 1 and coronary artery disease. N Engl J Med 2000; 342:1792-1801.
67. Ridker PM, Hennekens CH, Roitman-Johnson B, et al. Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men. Lancet 1998; 351:88-92.
68. Hwang SJ, Ballantyne CM, Sharrett AR, et al. Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk In Communities (ARIC) study. Circulation 1997; 96:4219-4225.
69. Blankenberg S, Rupprecht HJ, Bickel C, et al. Circulating cell adhesion molecules and death in patients with coronary artery disease. Circulation 2001; 104:1336-1342.
70. Pradhan AD, Rifai N, Ridker PM. Soluble intercellular adhesion molecule-1, soluble vascular adhesion molecule-1, and the development of symptomatic peripheral arterial disease in men. Circulation 2002; 106:820-825.
71. Tzoulaki I, Murray GD, Lee AJ, et al. C-reactive protein, interleukin-6, and soluble adhesion molecules as predictors of progressive peripheral atherosclerosis in the general population: Edinburgh Artery Study. Circulation 2005; 112:976-983.
72. Ridker PM, Vaughan DE, Stampfer MJ, et al. Endogenous tissue-type plas-minogen activator and risk of myocardial infarction. Lancet 1993; 341:1165-1168.
73. Spiel AO, Gilbert JC, Jilma B. von Willebrand factor in cardiovascular disease: focus on acute coronary syndromes. Circulation 2008; 117:1449-1459.
74. Blann AD, Lip GY, McCollum CN. Changes in von Willebrand factor and soluble ICAM, but not soluble VCAM, soluble E selectin or soluble thrombo-modulin, reflect the natural history of the progression of atherosclerosis. Atherosclerosis 2002; 165:389-391.
75. Tzoulaki I, Murray GD, Lee AJ, et al. Relative value of inflammatory, hemostatic, and rheological factors for incident myocardial infarction and stroke: the Edinburgh Artery Study. Circulation 2007; 115:2119-2127.
76. de Gaetano Donati K, Rabagliati R, Iacoviello L, Cauda R. HIV infection, HAART, and endothelial adhesion molecules: current perspectives. Lancet Infect Dis 2004; 4:213-222.
77. Ross AC, Rizk N, O'Riordan MA, et al. Relationship between inflammatory markers, endothelial activation markers, and carotid intima-media thickness in HIV-infected patients receiving antiretroviral therapy. Clin Infect Dis 2009; 49:1119-1127.
78. Riddler SA, Smit E, Cole SR, et al. Impact of HIV infection and HAART on serum lipids in men. JAMA 2003; 289:2978-2982.
79. Shlay JC, Bartsch G, Peng G, et al. Long-term body composition and metabolic changes in antiretroviral naive persons randomized to protease inhibitor-, nonnucleoside reverse transcriptase inhibitor-, or protease inhibitor plus nonnucleoside reverse transcriptase inhibitor-based strategy. J Acquir Immune Defic Syndr 2007; 44:506-517.
80. El-Sadr W, Mullin CM, Carr A, et al. Effects of HIV disease on lipid, glucose, and insulin levels: results from a large antiretroviral-naive cohort. HIV Med 2005; 6:114-121.
81. Kannel WB, Wilson PW. Efficacy of lipid profiles in prediction of coronary disease. Am Heart J 1992; 124:768-774.
82. Lewington S, Whitlock G, Clarke R, et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet 2007; 370:1829-1839.
83. Jeyarajah EJ, Cromwell WC, Otvos JD. Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy. Clin Lab Med 2006; 26:847-870.
84. Otvos JD, Collins D, Freedman DS, et al. Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial. Circulation 2006; 113:1556-1563.
85. Freedman DS, Otvos JD, Jeyarajah EJ, et al. Relation of lipoprotein subclasses as measured by proton nuclear magnetic resonance spectroscopy to coronary artery disease. Arterioscler Thromb Vasc Biol 1998; 18:1046-1053.